Sandoz Can't Escape Teva's Copaxone Patent Suit

By Allison Grande

Law360, New York (September 08, 2010, 5:53 PM ET) -- Sandoz Inc. and Momenta Pharmaceuticals Inc. have lost their bid to upend Teva Pharmaceuticals USA Inc.'s suit accusing the generic-drug makers of infringing several patents in their effort to manufacture a copycat version of multiple sclerosis drug Copaxone.

Judge Barbara S. Jones of the U.S. District Court for the Southern District of New York on Tuesday denied the defendants' motion for summary judgment, ruling that Sandoz and Momenta had failed to adequately prove that the asserted patents were invalid due to indefiniteness.

In a Dec. 23...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles